Research & Development News Channel

New compound targets enzyme linked to autoimmune disorders, severe COVID-19

When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.

New evidence COVID-19 antibodies, vaccines less effective against variants

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic. With few exceptions, whether such antibodies were produced in response to vaccination or natural infection, or were purified antibodies intended for use as drugs, the researchers found more antibody is needed to neutralize the new variants.

Vaccine development software shows promise in influenza effort, could help defeat coronavirus

A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.

Researchers discover SARS-CoV-2 inhibitors

A research team of pharmacists at the University of Bonn has discovered two families of active substances that can block the replication of the SARS-CoV-2 coronavirus. The drug candidates are able to switch off the the key enzyme of the virus, the so-called main protease. The study is based on laboratory experiments. Extensive clinical trials are still required for their further development as therapeutic drugs.

Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies

Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models.

According to new findings published in mBio, the vaccine produced potent neutralizing antibodies among preclinical models and also prevented infection and disease symptoms in the face of exposure to SARS-CoV-2 (the virus that causes COVID-19).

First COVID-19 COVAX vaccine doses administered in Africa

As the global rollout of COVAX vaccines accelerates, the first COVID-19 vaccination campaigns in Africa using COVAX doses began today in Ghana and Côte d'Ivoire. These campaigns are the among the first to use doses provided by the COVAX Facility’s Gavi COVAX Advanced Market Commitment (AMC).

The AMC is the COVAX Facility’s mechanism to provide donor-funded vaccines to lower-income countries.

Assessing a compound's activity, not just its structure, could accelerate drug discovery

Assessing a drug compound by its activity, not simply its structure, is a new approach that could speed the search for COVID-19 therapies and reveal more potential therapies for other diseases.

This action-based focus - called biological activity-based modeling (BABM) - forms the core of a new approach developed by National Center for Advancing Translational Sciences (NCATS) researchers and others.

Research & Development News

New compound targets enzyme linked to autoimmune disorders, severe COVID-19

New evidence COVID-19 antibodies, vaccines less effective against variants

Vaccine development software shows promise in influenza effort, could help defeat coronavirus

Researchers discover SARS-CoV-2 inhibitors

Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies

First COVID-19 COVAX vaccine doses administered in Africa

Assessing a compound's activity, not just its structure, could accelerate drug discovery

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs